Eclipsebio is the industry leader
for RNA solutions
Our world-class team of RNA experts develops unique assays and cutting-edge bioinformatics workflows that provide unparalleled insights for therapeutic development. Discover how our team can help you reduce drug development risks by designing and validating lead candidates.
We offer our portfolio of robust and reproducible assays in integrative platforms, tailored to the specific goals of different therapeutic classes and academic research goals. From deep characterization of mRNA drug products to developing datasets for training AI models, our team has experience solving the biggest problems in RNA-based and RNA-targeting therapeutics. Scroll below to learn more about our solutions and capabilities.
We provide complete
solutions for:
From novel approaches for designing and validating siRNAs to unparalleled insights for the development of mRNA vaccines, discover how we solve today’s challenges for tomorrow’s RNA medicines.
RNA Therapeutics
Our eMERGE partnership platform provides comprehensive characterization and precision optimization of RNA-based therapeutics. Discover how we support optimal translation and stability of vaccines, protein replacement therapies, and monoclonal antibodies.
Small Oligonucleotides
With our holistic approach to small oligonucleotide design and validation, we provide RNAi and ASO developers with the data needed for clinical success. Learn how we perform multiomic profiling of targets and robustly measure off-target effects.
Target Discovery and Validation
Our integrative portfolio of assays reveals disease-specific, accessible regions of target RNAs and provides deep profiling of on-target and off-target therapeutic effects. Our highly reproducible assays can also be used train AI models for the design of the next generation of small molecule drugs.
Our comprehensive capabilities
Unique technologies for unmatched insights
Our portfolio of proprietary technologies and bioinformatics workflows provide actionable insights for therapeutic characterization and optimization. Discover how a partnership with us provides exclusive access to the data and analyses needed for successful drug development.
End-Seq
Map unique regulatory regions
eRibo Pro
Measure transcription and translation
eSENSE dsRNA
Measure and reduce dsRNA contamination
eSENSE m6A
Map regions of RNA methylation
eSHAPE
Directly determine RNA structure
m6A-eCLIP
Locate specific methylated bases
miR-eCLIP
Identify miRNA binding and siRNA off-targets
RBP-eCLIP
Identify where and how proteins bind
Bioinformatics
Integrative analysis solutions
What Our Partners
and Collaborators Say
"Eclipsebio’s analysis of RNA folding has provided valuable insights necessary to understand the impact of RNA sequence and chemical modifications on secondary structures… to help improve the design of our RNAs and rationalize our internal findings."
"Eclipsebio was the only company that could perform the robust siRNA off-target binding analysis we needed. Their experimental results provided important additional insights into our own internal findings. We look forward to continuing to work with Eclipsebio in the future."
"Eclipsebio has been an invaluable partner to Deep Genomics. They've helped us generate massive miRNA-related datasets for training AI models, and have designed and conducted bespoke assays to illuminate the mechanism underlying some of our lead therapeutic compounds."
"At Acuitas we are interested in how modifications to LNP formulations can impact efficacy and stability. Eclipsebio’s eSHAPE assay has potentially revealed direct correlations between LNP composition and RNA secondary structure, further adding to our understanding of the mechanism of action for RNA-LNP systems."
New at Eclipsebio
Discover our latest platform
The effective development of an RNA-based medicine requires comprehensive characterization and precision optimization. With our eMERGE platform, therapeutic developers obtain access to our full portfolio of assays and bioinformatics workflows for drug development success.
Explore our newest technology
A major challenge with RNA vaccines and therapies is the generation of double-stranded RNA (dsRNA) by-products. With our eSENSE dsRNA assay you can measure the level of dsRNA contaminants and determine the sequences and structures that drive dsRNA generation.
Learn with our newest blog
RNA secondary structure is a key determinant of RNA biology and therapeutic efficacy. In this eBlog, we review how RNA structure affects the development of RNA vaccines, siRNAs, and ASOs.